Sue Fletcher

This inventor holds 44 USPTO granted patents and 25 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Antisense Oligonucleotides. Top assignees: The University of Western Australia, Murdoch University, Sarepta Therapeutics, Inc.. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sue Fletcher. Retrieved from https://idiyas.com/inventor/sue-fletcher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 25)

% Patents Active = 97.7

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 18)

Average Co-Inventor Count = 3.3

ph-index = 29

Forward Citations = 2,213(Granted Patents)

Company Filing History:

37 out of 109

The University of Western Australia

Sarepta Therapeutics, Inc.

patents

4. 2 out of 2

Vision Pharma Pty Ltd

patents

5. 2 out of 915

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Antisense Oligonucleotides

NEAT1 Disease

CFTR Function

Exon Skipping

Splicing Modulation

Multiple Sclerosis

Pathologies Treatment

Molecules

Gene Therapy

RNA Modulation

Therapeutics

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12709749 - ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES (2026-08-18),

2. 12649922 - Novel Retinitis Pigmentosa Treatment (2026-06-09),

3. 12559747 - Novel Retinitis Pigmentosa Treatment (2026-02-24),

4. 11459563 - Treatment for NEAT1 associated disease (2022-10-04),

5. 11447776 - Antisense molecules and methods for treating pathologies (2022-09-20),

6. RE48960 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2022-03-07),

7. 11236338 - Antisense-induced exon2 inclusion in acid alpha-glucosidase (2022-02-01),

8. 10995337 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-05-04),

9. 10968450 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2021-04-06),

10. 10781451 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2020-09-22),

11. 10781450 - Antisense molecules and methods for treating pathologies (2020-09-22),

12. 10731156 - Restoration of the CFTR function by splicing modulation (2020-08-04),

13. RE47769 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-12-16),

14. RE47751 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-12-02),

15. RE47691 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof (2019-11-04),

Title: Celebrating the Innovations of Sue Fletcher

Introduction

Sue Fletcher is a prominent inventor based in Bayswater, Australia, known for her groundbreaking contributions to the field of biomedical research. With an impressive portfolio of 41 patents, her work has significantly advanced the understanding and treatment of various diseases, particularly those related to RNA processing.

Latest Patents

Fletcher's latest patents demonstrate her innovative approach to addressing complex medical challenges. One notable patent is focused on a treatment for NEAT1 associated disease, which centers on an isolated or purified antisense oligomer designed to modify RNA cleavage and processing in the NEAT1 gene transcript. Another significant patent involves antisense molecules and methods for treating pathologies. This invention presents an antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, highlighting her commitment to developing therapies for genetic conditions.

Career Highlights

Throughout her career, Sue Fletcher has made remarkable strides in the academic realm. She has been affiliated with reputable institutions such as The University of Western Australia and Murdoch University, where she has contributed her expertise to various research projects and initiatives. Her extensive background in biomedical research underscores her dedication to innovation and the pursuit of new medical solutions.

Collaborations

Fletcher has collaborated with notable figures in her field, including Stephen Donald Wilton and Graham McClorey. These collaborations have facilitated the sharing of ideas and expertise, further advancing the development of her innovative treatments and research initiatives.

Conclusion

Sue Fletcher's work exemplifies the spirit of innovation in biomedical research. With her substantial number of patents and collaborative efforts, she continues to impact the scientific community positively. Her dedication to addressing complex health issues through her inventions ensures that she remains an influential figure in the field.

Profile summary based on public USPTO records.